Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an...
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has earned an average rating of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among analysts […]
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 481.40% from the stock’s previous close. Several […]
– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023...